YLYanshu Li

Yanshu Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanshu Li has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Andreiv Sergee

    Electrical Engineering Department, University at Buffalo — SUNY, Buffalo, NY 14260, USA

    1 shared publication
  • Bingtao Hu

    Department of Cell Biology, Key Laboratory of Cell Biology of National Health Commission of the PRC, Key Laboratory of Medical Cell Biology of Ministry of Education of the PRC, China Medical University, No.77, Puhe Road, Shenyang, 110122, Liaoning, China

    1 shared publication
  • Danni Li

    Department of Lab Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA

    1 shared publication
  • Degang Sun

    Institute of International Studies, Fudan University

    1 shared publication
  • Feng Jin

    Department of Breast Surgery The First Hospital of China Medical University Shenyang Liaoning China

    1 shared publication
  • Feng Li

    Department of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, School of Life Sciences, China Medical University, Shenyang, China

    1 shared publication

Latest Publications

  • ASGNet: Adaptive Semantic Gate Networks for Log-Based Anomaly Diagnosis

    by Haitian Yang, Degang Sun, Wen Liu, Yanshu Li, Yan Wang, Weiqing Huang


  • Open Access

    Change in the sub-sesamoid soft tissue thickness under different loading conditions

    by Zijian Liu, Toshihiro Maemichi, Masatomo Matsumoto, Takumi Okunuki, Hirofumi Tanaka, Hirofumi Katsutani, Yanshu Li, Tsukasa Kumai

    [Purpose] To measure the sub-sesamoid soft tissue thickness change from non-loading to self-weight loading conditions. [Participants and Methods] The study included 17 female participants for the study. A questionnaire was used to collect the demographic data and participant anamnesis, such as the presence of foot injuries and diabetes. The measured height and weight were used to calculate the body mass index. Participants were required to stand on an evaluation device from non-loading to 100% loading conditions to measure the sub-sesamoid soft tissue thickness. [Results] Significant differences were observed between the tibial and fibular sub-sesamoid soft tissue thicknesses under non-loading and all loading conditions. Significant soft tissue thinning was observed with a change from non-loading to 25% loading condition. However, no significant differences in the rate of change were observed between the tibial and fibular sub-sesamoid soft tissue thicknesses at 100% loading. [Conclusion] The sub-fibular sesamoid soft tissue was thicker than the sub-tibial sesamoid soft tissue in all loading conditions. The sub-sesamoid soft tissue thickness change was larger during initial loading stage than during the late loading stage, which may be normal in healthy females in their 20s.

  • Open Access

    The Impact of Higher Education to Manufacturing-Based on Threshold Model

    by Yaodong Bao, Yanshu Li, Junshen Chen

    This paper examines the impact of higher education on China’s manufacturing industry performance from the national and regional levels on fixed effects model. The research shows that the development of higher education has significantly promoted the improvement of China’s manufacturing industry performance. If the development of higher education increases by 1%, the performance of manufacturing industry will increase by 0.239%. Through the internal mechanism test, it is found that higher education can improve the performance of manufacturing industry by increasing the R&D projects, new product projects and enterprise invention patents. Further research shows that there is a double threshold nonlinear relationship between higher education and manufacturing industry performance with per capita GDP and government financial science and technology expenditure as threshold variables based on threshold model.

  • Open Access

    PAK5-mediated AIF phosphorylation inhibits its nuclear translocation and promotes breast cancer tumorigenesis

    by Yao Xing, Yang Li, Bingtao Hu, Fuyi Han, Xin Zhao, Hongyan Zhang, Yanshu Li, Danni Li, Jiabin Li, Feng Jin, et al.

    Although p21 activated kinase 5 (PAK5) is related to the progression of multiple cancers, its biological function in breast cancer remains unclear. Apoptosis-inducing factor (AIF) is a vital apoptosis factor in mitochondria, which can be released from mitochondria and enter the nucleus, causing caspase-independent apoptosis. In this study, we reveal that PAK5 inhibits apoptosis by preventing the nuclear translocation of AIF. PAK5 inhibits the release of AIF from mitochondria in breast cancer cells by decreasing the mitochondria membrane permeability and increasing the membrane potential. Furthermore, PAK5 phosphorylates AIF at Thr281 site to inhibit the formation of AIF/importin α3 complex, leading to decrease AIF nuclear translocation. Functionally, we demonstrate that PAK5-mediated AIF phosphorylation promotes the proliferation of breast cancer cells and accelerates the growth of breast cancer in vivo. Significantly, PAK5 and AIF expression in breast cancer are positively correlated with poor patient prognosis. PAK5 expression is negatively correlated with AIF nuclear translocation. These results suggest that PAK5-AIF signaling pathway may play an essential role in mammary tumorigenesis, providing a new therapeutic target for the treatment of breast cancer.


  • Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?

    by Xin Fu, Yan-Shu Li, Jun Zhao, Lu-Lu Yu, Rong-Guang Luo, Qing-Rong Liang, Qun Tang

    Arsenic trioxide (ATO) has remarkably enhanced therapeutic efficacy in treating both newly diagnosed and relapsed patients suffering from Acute Promyelocytic Leukemia (APL). Unfortunately, whether as a single agent, component of combined chemotherapy, or as a chemosensitizer or radiosensitizer combined with interventional therapy/radiotherapy, it did not benefit treatment of solid tumor (liver cancer, bladder cancer, glioma, breast cancer, cervical cancer, colorectal cancer, lung cancer, and melanoma) as seen from the clinical trials reported from the published journals or FDA-approved trials in the past decades. The clinical outcome failed to live up to our expectations, which was attributed to severe systemic toxicity and inappropriate pharmacokinetic such as low delivery efficiency and rapid renal elimination. Nanomedicine is designed to fuel up pharmaceuticals and polish off adverse effects by the moderation of their absorption, distribution, metabolism, and excretion. Nevertheless, quite a few nanodrugs (such as Doxil, Abraxane) were approved to be used clinically, and “from bench to bedside” it seems to be no easy way for most of them, such as nano-ATO. Encapsulating ATO into several types of nano-vehicles (liposome, polymer micelle, porous silicon, etc.), nano-TO can improve pharmacokinetic and become a prominent candidate to penetrate into tumor tissue, but so far no nano- ATO clinical trials have been approved around the world. On summarizing the clinical trials of ATO on solid tumor and preclinical study of nano-ATO, it is believed there is still a chance for ATO to play a critical co-helper in a comprehensive therapy to fight with solid tumor.